News headlines about Savara (NASDAQ:SVRA) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Savara earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.6638526251686 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Savara stock traded down $0.19 during trading on Wednesday, hitting $11.02. The company’s stock had a trading volume of 2,759 shares, compared to its average volume of 233,433. The company has a quick ratio of 10.30, a current ratio of 10.30 and a debt-to-equity ratio of 0.16. Savara has a 52 week low of $5.26 and a 52 week high of $17.19. The stock has a market cap of $412.71 million, a price-to-earnings ratio of -6.26 and a beta of -0.33.
Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.02). equities analysts anticipate that Savara will post -1.41 earnings per share for the current fiscal year.
A number of research firms have weighed in on SVRA. BidaskClub raised shares of Savara from a “hold” rating to a “buy” rating in a research note on Wednesday, June 20th. Zacks Investment Research raised shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 23rd. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Savara in a research note on Friday, August 10th. Canaccord Genuity set a $25.00 target price on shares of Savara and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, Roth Capital began coverage on shares of Savara in a research note on Monday, August 13th. They set a “neutral” rating and a $12.00 target price on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $22.94.
In related news, CEO Robert N. Neville sold 2,737 shares of the business’s stock in a transaction on Friday, June 8th. The shares were sold at an average price of $12.13, for a total value of $33,199.81. Following the transaction, the chief executive officer now owns 402,648 shares in the company, valued at $4,884,120.24. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jaakko Taneli Jouhikainen sold 2,638 shares of the business’s stock in a transaction on Friday, June 8th. The shares were sold at an average price of $12.11, for a total transaction of $31,946.18. Following the completion of the transaction, the insider now owns 207,688 shares in the company, valued at approximately $2,515,101.68. The disclosure for this sale can be found here. In the last three months, insiders sold 47,055 shares of company stock worth $569,209. 6.10% of the stock is currently owned by insiders.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.